Oppenheimer Comments on Seattle Genetics (SGEN) After 2012 ASCO
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Price: $228.74 --0%
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Oppenheimer commented on Seattle Genetics (NASDAQ: SGEN) after this weekend's ASCO. The firm said adcetris retreatment/new indications becoming clearer.
The firm comments, "In the ongoing ph.II retreatment study, Adcetris demonstrated 70%/88% ORR for HL/ALCL (n=14/8), respectively. Importantly, the ORR in this trial continues to be very strong, and we expect growing interest in retreatment for Adcetris in HL/ALCL. Additionally, non-lymphoma screening data showed elevated CD30 expression in mesothelioma (28%), melanoma (9%), triple negative breast cancer (6%), and ovarian cancer (5%), which could represent sizable new commercial opportunities for Adcetris. Last, Adcetris showed encouraging activity in a ph.II relapsed/refractory CD30+ NHL trial (n=14), with a 36% ORR."
The firm maintained their Outperform rating and price target of $26.00.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $19.11 yesterday.
The firm comments, "In the ongoing ph.II retreatment study, Adcetris demonstrated 70%/88% ORR for HL/ALCL (n=14/8), respectively. Importantly, the ORR in this trial continues to be very strong, and we expect growing interest in retreatment for Adcetris in HL/ALCL. Additionally, non-lymphoma screening data showed elevated CD30 expression in mesothelioma (28%), melanoma (9%), triple negative breast cancer (6%), and ovarian cancer (5%), which could represent sizable new commercial opportunities for Adcetris. Last, Adcetris showed encouraging activity in a ph.II relapsed/refractory CD30+ NHL trial (n=14), with a 36% ORR."
The firm maintained their Outperform rating and price target of $26.00.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $19.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
- Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
